對FFR指導(dǎo)冠脈臨界病變延遲PCI的分析
發(fā)布時(shí)間：2019-04-22 08:26
【摘要】：目的本研究通過對冠脈造影提示臨界病變者,以心肌血流儲備分?jǐn)?shù)為指導(dǎo)來決定是否行介入治療,分別隨訪術(shù)后1個(gè)月、6個(gè)月、12個(gè)月嚴(yán)重心絞痛發(fā)作情況、運(yùn)動試驗(yàn)陽性和主要不良心血管事件的發(fā)生情況,借此來評價(jià)心肌血流儲備分?jǐn)?shù)在指導(dǎo)冠脈臨界病變延遲PCI的價(jià)值。方法連續(xù)選取于2014年1月至2014年11月,診斷不穩(wěn)定性心絞痛,在某醫(yī)院心內(nèi)科住院治療,接受冠脈造影(CAG)檢查結(jié)果示冠脈血管局限性的臨界病變者,病變參考血管直徑(RD)大于2.5mm,且病變的直徑狹窄率(DS)介于50%至70%之間的患者94例。分成三組,CAG藥物治療組、FFR延遲治療組、FFR介入治療組。其中CAG藥物治療組34例,給予最優(yōu)化藥物治療;FFR延遲治療組30例是對FFR075的病變不進(jìn)行PCI治療僅給予規(guī)范的冠心病二級預(yù)防藥物治療;FFR介入治療組30例是對FFR≤0.75的病變行PCI治療,行PCI治療者均植入藥物涂層支架。所有患者均給予最優(yōu)化的冠心病二級預(yù)防治療。術(shù)后分別隨訪1個(gè)月、6個(gè)月、12個(gè)月,觀察隨訪期間三組TG、LDL-C、HDL、LDH、CK、CKMB、c TN-I、NT-pro BNP、LVEF數(shù)值、運(yùn)動實(shí)驗(yàn)的變化分別在術(shù)后1個(gè)月、6個(gè)月、12個(gè)月有無統(tǒng)計(jì)學(xué)差異;并隨訪三組在MACE(主要不良心臟事件)包括死亡、非致死性心肌梗死、靶血管血運(yùn)重建和嚴(yán)重心絞痛發(fā)作情況(這里指CCS心絞痛分級Ⅲ級以上)有無差異來評價(jià)FFR指導(dǎo)下延遲治療組的效果。結(jié)果所有患者均完成隨訪,無一人失訪。結(jié)果顯示三組患者在年齡、性別、吸煙史、高血壓、高脂血癥、糖尿病、化驗(yàn)指標(biāo)(TG、HDL、LDH、CK、CK-MB、c TN-I、NT-pro BNP)、左室射血分?jǐn)?shù)(LVEF值)、血管病變分布等臨床特征方面沒有統(tǒng)計(jì)學(xué)差異(P0.05)。FFR介入治療組植入支架34枚(1.10±0.30),行支架植入者支架均植入成功,術(shù)后血流達(dá)TIMI3級。三組患者均給予最優(yōu)化藥物治療開展冠心病二級預(yù)防。三組患者化驗(yàn)資料、LVEF在隨訪中比較無顯著統(tǒng)計(jì)學(xué)差異(P0.05)。術(shù)后隨訪顯示第1個(gè)月和第6個(gè)月均未發(fā)生MACE,運(yùn)動實(shí)驗(yàn)和嚴(yán)重心絞痛發(fā)作情況無顯著統(tǒng)計(jì)學(xué)差異(P0.05)。隨訪12個(gè)月結(jié)果示三組病例在MACE上無明顯統(tǒng)計(jì)學(xué)意義(P0.05)。三組病例在運(yùn)動試驗(yàn)陽性方面差異有統(tǒng)計(jì)學(xué)意義(P0.05),CAG藥物治療組運(yùn)動試驗(yàn)陽性率最高,FFR延遲治療組居中,FFR介入治療組最低;兩兩比較顯示:FFR介入治療組與CAG藥物治療組間以及FFR延遲治療組CAG藥物治療組間差異均有統(tǒng)計(jì)學(xué)意義(P0.05);FFR介入治療組與FFR延遲治療組間差異不顯著(P0.05)。三組病例在嚴(yán)重心絞痛發(fā)作方面差異有統(tǒng)計(jì)學(xué)意義(P0.05),CAG藥物治療組嚴(yán)重心絞痛發(fā)生率最高;兩兩比較顯示:FFR介入治療組與CAG藥物治療組間差異最顯著(P0.05);FFR延遲治療組與FFR介入治療組間及FFR延遲治療組與CAG藥物治療組差異不顯著。臨界病變運(yùn)動試驗(yàn)陽性者更傾向于PCI。結(jié)論1 FFR指導(dǎo)下延遲PCI藥物治療沒有增加MACE的風(fēng)險(xiǎn),FFR在指導(dǎo)冠狀動脈臨界病變延遲PCI安全可靠;2 FFR指導(dǎo)臨界病變介入治療可以降低嚴(yán)重心絞痛發(fā)作、運(yùn)動平板陽性的發(fā)生,改善心肌缺血,提高運(yùn)動耐力;FFR指導(dǎo)下延遲PCI治療同樣可以改善心肌缺血,提高運(yùn)動耐力。
[Abstract]:Objective To study the effect of coronary angiography on the critical lesion of angina pectoris, and to determine whether to perform interventional therapy on the basis of myocardial blood flow reserve score, and follow-up of 1-month,6-month and 12-month severe angina pectoris after follow-up. The occurrence of positive and major adverse cardiovascular events in the exercise test is used to evaluate the value of myocardial blood flow reserve in the guidance of the delayed PCI of the critical coronary artery disease. Methods From January 2014 to November 2014, the patients with unstable angina pectoris were diagnosed with unstable angina pectoris. The results of coronary angiography (CAG) and coronary angiography (CAG) were used to show the critical lesions of the limitation of the coronary artery. The reference vessel diameter (RD) of the lesion was greater than 2.5 mm. And the stenosis rate (DS) of the lesion was between 50 and 70% of the patients. Three groups were divided into three groups: the CAG drug treatment group, the FFR delayed treatment group, and the FFR intervention treatment group. in which 34 of the CAG drug treatment groups were treated with an optimized drug; the FFR delayed treatment group 30 was a coronary heart disease secondary prevention drug treated only by the PCI treatment for the lesion of the FFR075; the FFR intervention treatment group 30 was a lesion line PCI treatment of the FFR group 0.75, All PCI-treated patients were implanted with a drug-coated stent. All patients were given the optimized secondary prevention of coronary heart disease. Three groups of TG, LDL-C, HDL, LDH, CK, CKMB, c-TN-I, NT-pro BNP and LVEF were followed up for 1 month,6 months and 12 months, respectively. The effectiveness of the delayed treatment group under FFR guidance was evaluated with the presence or absence of differences in the MACE (major adverse cardiac events), including death, non-fatal myocardial infarction, target vessel revascularization, and severe angina (here, CCS angina grade III or above). Results All patients were followed up and no one was lost to follow-up. The results showed that the three groups were in age, sex, smoking history, hypertension, hyperlipidemia, diabetes, test index (TG, HDL, LDH, CK, CK-MB, c TN-I, NT-pro BNP) and left ventricular ejection fraction (LVEF). There was no statistical difference in the clinical features such as the distribution of vascular lesions (P0.05). The FFR was implanted in 34 (1.10, 0.30), and the stent-implanted stents were successfully implanted and the blood flow reached the TITI3 stage. The second prevention of coronary heart disease was carried out in three groups of patients. There was no significant difference between the three groups (P0.05). There was no significant difference in the incidence of MACE, exercise and severe angina in the first and sixth months after the operation (P0.05). The results of 12-month follow-up showed no significant difference in MACE (P0.05). There was a significant difference in the positive aspects of the three groups (P0.05). The positive rate of the exercise test in the CAG group was the highest, the FFR delayed treatment group was the lowest, and the FFR was the lowest in the treatment group, and the two comparisons showed that: There was no significant difference between the treatment groups of the FFR intervention group and the CAG drug treatment group and the group of the FFR delayed treatment group (P0.05); the difference between the FFR intervention treatment group and the FFR delayed treatment group was not significant (P0.05). There was a significant difference in the incidence of severe angina (P0.05). The incidence of severe angina in the treatment group was the highest in the treatment group of CAG. The two comparisons showed that the difference between the two groups was the most significant (P0.05). The difference between the FFR-delayed treatment group and the FFR-delayed treatment group and the FFR-delayed treatment group was not significant. The patients with critical lesion movement were more prone to PCI. Conclusion 1 FFR-guided PCI drug therapy did not increase the risk of MACE. FFR was safe and reliable to guide the delayed PCI of the coronary critical lesion. FFR-guided interventional therapy could reduce the onset of severe angina, the occurrence of positive plate positive, and improve the myocardial ischemia. Improve that endurance of exercise; the delayed PCI treatment under the guidance of FFR can also improve the myocardial ischemia and improve the exercise endurance.
【學(xué)位授予單位】：華北理工大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R54
本文編號：2462677
[Abstract]:Objective To study the effect of coronary angiography on the critical lesion of angina pectoris, and to determine whether to perform interventional therapy on the basis of myocardial blood flow reserve score, and follow-up of 1-month,6-month and 12-month severe angina pectoris after follow-up. The occurrence of positive and major adverse cardiovascular events in the exercise test is used to evaluate the value of myocardial blood flow reserve in the guidance of the delayed PCI of the critical coronary artery disease. Methods From January 2014 to November 2014, the patients with unstable angina pectoris were diagnosed with unstable angina pectoris. The results of coronary angiography (CAG) and coronary angiography (CAG) were used to show the critical lesions of the limitation of the coronary artery. The reference vessel diameter (RD) of the lesion was greater than 2.5 mm. And the stenosis rate (DS) of the lesion was between 50 and 70% of the patients. Three groups were divided into three groups: the CAG drug treatment group, the FFR delayed treatment group, and the FFR intervention treatment group. in which 34 of the CAG drug treatment groups were treated with an optimized drug; the FFR delayed treatment group 30 was a coronary heart disease secondary prevention drug treated only by the PCI treatment for the lesion of the FFR075; the FFR intervention treatment group 30 was a lesion line PCI treatment of the FFR group 0.75, All PCI-treated patients were implanted with a drug-coated stent. All patients were given the optimized secondary prevention of coronary heart disease. Three groups of TG, LDL-C, HDL, LDH, CK, CKMB, c-TN-I, NT-pro BNP and LVEF were followed up for 1 month,6 months and 12 months, respectively. The effectiveness of the delayed treatment group under FFR guidance was evaluated with the presence or absence of differences in the MACE (major adverse cardiac events), including death, non-fatal myocardial infarction, target vessel revascularization, and severe angina (here, CCS angina grade III or above). Results All patients were followed up and no one was lost to follow-up. The results showed that the three groups were in age, sex, smoking history, hypertension, hyperlipidemia, diabetes, test index (TG, HDL, LDH, CK, CK-MB, c TN-I, NT-pro BNP) and left ventricular ejection fraction (LVEF). There was no statistical difference in the clinical features such as the distribution of vascular lesions (P0.05). The FFR was implanted in 34 (1.10, 0.30), and the stent-implanted stents were successfully implanted and the blood flow reached the TITI3 stage. The second prevention of coronary heart disease was carried out in three groups of patients. There was no significant difference between the three groups (P0.05). There was no significant difference in the incidence of MACE, exercise and severe angina in the first and sixth months after the operation (P0.05). The results of 12-month follow-up showed no significant difference in MACE (P0.05). There was a significant difference in the positive aspects of the three groups (P0.05). The positive rate of the exercise test in the CAG group was the highest, the FFR delayed treatment group was the lowest, and the FFR was the lowest in the treatment group, and the two comparisons showed that: There was no significant difference between the treatment groups of the FFR intervention group and the CAG drug treatment group and the group of the FFR delayed treatment group (P0.05); the difference between the FFR intervention treatment group and the FFR delayed treatment group was not significant (P0.05). There was a significant difference in the incidence of severe angina (P0.05). The incidence of severe angina in the treatment group was the highest in the treatment group of CAG. The two comparisons showed that the difference between the two groups was the most significant (P0.05). The difference between the FFR-delayed treatment group and the FFR-delayed treatment group and the FFR-delayed treatment group was not significant. The patients with critical lesion movement were more prone to PCI. Conclusion 1 FFR-guided PCI drug therapy did not increase the risk of MACE. FFR was safe and reliable to guide the delayed PCI of the coronary critical lesion. FFR-guided interventional therapy could reduce the onset of severe angina, the occurrence of positive plate positive, and improve the myocardial ischemia. Improve that endurance of exercise; the delayed PCI treatment under the guidance of FFR can also improve the myocardial ischemia and improve the exercise endurance.
【學(xué)位授予單位】：華北理工大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R54
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 焦繼峰;;探討不同治療時(shí)機(jī)對新診斷癲癇患者復(fù)發(fā)的影響[J];中國醫(yī)療前沿;2013年17期
2 馮畹蘭;小兒痔六例報(bào)告[J];白求恩醫(yī)科大學(xué)學(xué)報(bào);1989年04期
3 何桂香,陳亞平,唐湘華;老年急性心肌梗死病人延遲治療相關(guān)原因分析及對策[J];護(hù)理學(xué)雜志;2004年11期
4 辛玉湖;小兒肺不張延遲治療1例報(bào)告[J];陜西醫(yī)學(xué)雜志;1999年07期
5 李鵬;;腦血栓決定延遲治療的單因素分析[J];中國病案;2009年11期
6 馬成文,郭懷宸,黃玲;兒童特殊類型癲癇47例報(bào)告[J];醫(yī)學(xué)理論與實(shí)踐;1997年10期
7 莫光洲;;無創(chuàng)呼吸機(jī)早期治療和延遲治療在COPD急性發(fā)作中的效果[J];泰山醫(yī)學(xué)院學(xué)報(bào);2014年05期
8 曹建春;;九種癥狀幫您識別“近中風(fēng)期”[J];健康管理;2013年09期
9 程平,高云,侯素俠;妊娠期急性闌尾炎手術(shù)36例診治體會[J];實(shí)用鄉(xiāng)村醫(yī)生雜志;1997年01期
10 Tacushi M ,袁素華;子宮頸浸潤性癌合并妊娠延遲治療的結(jié)果[J];實(shí)用婦產(chǎn)科雜志;2003年04期
相關(guān)會議論文 前1條
1 王彤;吳玉梅;宋芳;朱力;李寶珠;郝霞;孔為民;段微;范玲;張為遠(yuǎn);;妊娠期宮頸微小浸潤鱗癌延遲治療的孕期觀察和母嬰結(jié)局[A];中華醫(yī)學(xué)會第十次全國婦產(chǎn)科學(xué)術(shù)會議婦科腫瘤會場（婦科腫瘤學(xué)組、婦科病理學(xué)組）論文匯編[C];2012年
相關(guān)重要報(bào)紙文章 前1條
1 記者 崔立新;多動癥癥狀可持續(xù)到成年期[N];中國人口報(bào);2007年
相關(guān)碩士學(xué)位論文 前2條
1 史蘇娜;對FFR指導(dǎo)冠脈臨界病變延遲PCI的分析[D];華北理工大學(xué);2016年
2 晏玉奎;新診斷癲癇患者早期藥物治療的系列研究[D];南京醫(yī)科大學(xué);2010年
，本文編號：2462677
本文鏈接：http://www.sikaile.net/yixuelunwen/xxg/2462677.html
最近更新
教材專著
